253 related articles for article (PubMed ID: 16846554)
1. Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.
Hanefeld M; Pfützner A; Forst T; Lübben G
Curr Med Res Opin; 2006 Jun; 22(6):1211-5. PubMed ID: 16846554
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
Raz I; Stranks S; Filipczak R; Joshi P; Lertoft B; Rastam J; Chow CC; Shaban J
Clin Ther; 2005 Sep; 27(9):1432-43. PubMed ID: 16291416
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Piccinni MN; D'Angelo A; Fogari E; Maffioli P
Diabetes Technol Ther; 2013 Mar; 15(3):214-22. PubMed ID: 23427864
[TBL] [Abstract][Full Text] [Related]
4. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and β-cell function: the triple oral therapy.
Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Piccinni MN; D'Angelo A; Fogari E; Maffioli P
Diabet Med; 2013 Jul; 30(7):846-54. PubMed ID: 23413771
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
Kaku K
Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
[TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.
Comaschi M; Demicheli A; Di Pietro C; Bellatreccia A; Mariz S;
Diabetes Technol Ther; 2007 Aug; 9(4):387-98. PubMed ID: 17705695
[TBL] [Abstract][Full Text] [Related]
7. β-cell function preservation after 3.5 years of intensive diabetes therapy.
Harrison LB; Adams-Huet B; Raskin P; Lingvay I
Diabetes Care; 2012 Jul; 35(7):1406-12. PubMed ID: 22723578
[TBL] [Abstract][Full Text] [Related]
8. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.
Panikar V; Chandalia HB; Joshi SR; Fafadia A; Santvana C
J Assoc Physicians India; 2003 Nov; 51():1061-4. PubMed ID: 15260389
[TBL] [Abstract][Full Text] [Related]
10. Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Charpentier G; Halimi S;
Diabetes Obes Metab; 2009 Sep; 11(9):844-54. PubMed ID: 19614944
[TBL] [Abstract][Full Text] [Related]
11. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
Kvapil M; Swatko A; Hilberg C; Shestakova M
Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
[TBL] [Abstract][Full Text] [Related]
12. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
14. Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy.
Raz I; Mouritzen U; Vaz J; Hershkovitz T; Wainstein J; Harman-Boehm I
Clin Ther; 2003 Dec; 25(12):3109-23. PubMed ID: 14749149
[TBL] [Abstract][Full Text] [Related]
15. Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.
Pandya BJ; Bron M; McCall T; Yu AP; Chen KS; Mattson ME; Wu EQ
Curr Med Res Opin; 2011 Jan; 27(1):189-95. PubMed ID: 21142610
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
Hamann A; Garcia-Puig J; Paul G; Donaldson J; Stewart M
Exp Clin Endocrinol Diabetes; 2008 Jan; 116(1):6-13. PubMed ID: 18095238
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
[TBL] [Abstract][Full Text] [Related]
18. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.
Yamanouchi T; Sakai T; Igarashi K; Ichiyanagi K; Watanabe H; Kawasaki T
Diabet Med; 2005 Aug; 22(8):980-5. PubMed ID: 16026361
[TBL] [Abstract][Full Text] [Related]
19. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
20. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Norwood P; Liutkus JF; Haber H; Pintilei E; Boardman MK; Trautmann ME
Clin Ther; 2012 Oct; 34(10):2082-90. PubMed ID: 23031623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
